| 摘要 |
The use of angiotensin-converting-enzyme (ACE) inhibitors of formula (I) or their salts in the prodn. of medicaments for treatment of cardiac insufficiency in mammals is claimed. n = 1 or 2; R = H, ORa, SRa or an opt. substd. 1-8C aliphatic, 3-9C alicyclic, 6-12C aromatic, 7-14C araliphatic or 7-14C alicyclic-aliphatic gp.; Ra = an opt. substd. 1-4C aliphatic, 6-12C aromatic or 5- to 12-membered heteroaromatic gp.; R1 = H, an opt. substd. 1-6C aliphatic, 3-9C alicyclic, 4-13C alicyclicaliphatic, 6-12C aromatic, 7-16C araliphatic or 5- to 12-membered heteroaromatic gp., or the opt. protected side chain of a natural alpha-amino acid; R2 and R3 = H or opt. substd. 1-6C aliphatic, 3-9C alicyclic, 6-12C aromatic or 7-16C araliphatic gps.; R4+R5 completes a 5-15C mono-, bi- or tricyclic heterocyclic ring system. (I) are described in DE 3211397, DE3227055 and EP 46953, 79022, 84164, 89637 and 90362. |
